Aug 2026· Journal of Controlled Release· Vol 399, pp.
115317
· 0 citations· 64 references
Medicine
TL;DR
It is demonstrated that LNPs can be combined with NLS peptides to promote non-viral DNA delivery to the nucleus by endogenous nuclear import pathways.
Abstract
Efficient nuclear delivery of DNA remains a significant challenge for non-viral vectors, limiting their broader application in gene therapy. A key intracellular barrier is represented by the nuclear envelope, where the nuclear pore complex (NPC) restricts passive diffusion of macromolecules, and prevents more than 97% of delivered cytosolic DNA from entering the nucleus. Our study addresses this major limitation with a targeted delivery strategy leveraging nuclear localization signaling (NLS) peptides to enhance nuclear import of plasmid DNA (pDNA). NLS peptides were non-covalently complexed with pDNA and co-encapsulated in lipid nanoparticles (LNPs). Using fluorescently labeled LNPs and pDNA, the intracellular trafficking behavior from cellular uptake to endosomal escape and nuclear entry was characterized with and without the co-encapsulation of the NLS peptide. pDNA-NLS-functionalized LNPs achieved a 2.5-fold increase in transfection efficiency compared to non-complexed controls in vitro. Mechanistic studies indicate that cytosolic importins recognize the co-delivered NLS peptides, facilitating active transport of the released pDNA through the nuclear pore complex. In vivo studies in zebrafish larvae and wildtype mice are consistent with an NLS-dependent enhancement in gene expression, displaying a 10-fold increase after 72 h in mice. These findings demonstrate that LNPs can be combined with NLS peptides to promote non-viral DNA delivery to the nucleus by endogenous nuclear import pathways.
Oligonucleotide therapeutics have great potential for the treatment of previously "undruggable" human diseases; however, their broad utility is limited by challenges in delivery and achieving sufficient endosomal escape. Systemic delivery of antisense oligonucleotides (ASOs) results in their primary accumulation in the...
Priyanka Mangla, Emma Kay, M. J. Munson et al.· Nucleic Acid Therapeutics· 0 citations
The importance of formulation optimization in improving nucleic acid delivery is highlighted and practical insights for enhancing peptide- and lipid-based therapeutic platforms are provided.
D. Daniele, Z. Hein, O. Saher et al.· International Journal of Pha...· 0 citations
Molecular simulations are employed to elucidate how LNPs fuse with the endosomal membrane and release their payloads, and identify multiple fusion pathways, with a dominant stalk-pore mechanism.
A. P. Singh, Kana Shibata, Yusuke Miyazaki et al.· bioRxiv· 0 citations
Introduction Lipid nanoparticles (LNPs) have enabled the clinical translation of nucleic acid therapeutics, and their composition plays a critical role in organ targeting and route-specific delivery. Intranasal (IN) administration offers direct access to the lungs, while reducing systemic exposure. However, designing L...
M. T. Rodrigues Alves, Walison Nunes da Silva, Gabriel Vieira Azevedo et al.· International Journal of Nan...· 0 citations
Human T cells modified with nucleic acids constitute a powerful and emerging therapeutic modality for cancer, autoimmune disorders, and aging-related diseases. However, delivering nucleic acids, such as mRNA encoding synthetic receptors, transcription factors, cytokines, or genome editors to T cells can be challenging,...
Apoorva Ramamurthy, Giulia Scimonelli, William L. Murphy et al.· Molecular Therapy: Nucleic A...· 0 citations
The optimized nanocarrier promoted efficient uptake of fluorescent siRNA in MDA-MB-231 cells and achieved functional delivery of anti-EGFR, leading to substantially reduced expression of the target gene at both transcript and protein levels.
P. Białecki, S. Braccia, T. Makowski et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.